Companies Applying AI to De-Risk Clinical Trials: 2026 Watchlist

Clinical development is still shaped by a stubborn asymmetry: only around one in ten drug candidates that enter human testing ever reaches approval, and Phase II/III failures remain the biggest drivers of wasted R&D spend. Despite growing use of de-risking strategies such as genetics-anchored target selection, increasing use of biomarker-stratified …

9 Notable AI Companies in Clinical Research to Watch in 2023

The clinical trial is a critical stage of drug development workflow, with an estimated average success rate of about 11% for drug candidates moving from Phase 1 towards approval. Even if the drug candidate is safe and efficacious, clinical trials might fail due to the lack of financing, insufficient enrollment, …